NASDAQ · OVID
Ovid Therapeutics Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for OVID: Nov 11, 2026
Ovid Therapeutics Inc. Common Stock is estimated to report earnings on 11/11/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 7 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.08. The reported EPS for the same quarter last year was $-0.17.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.08 | $-0.05 | $-0.10 | 7 |
| Dec 2026 | $-0.09 | $-0.08 | $-0.11 | 7 |
| Mar 2027 | $-0.09 | $-0.08 | $-0.10 | 4 |
| Jun 2027 | $-0.09 | $-0.07 | $-0.11 | 4 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · RTTNews · Zacks · The Motley Fool- Fintel · Oct 9, 11:19 AM EDTCantor Fitzgerald Initiates Coverage of Ovid Therapeutics with Overweight RatingFintel reports that on October 9, 2026, Cantor Fitzgerald initiated coverage of Ovid Therapeutics (NASDAQCM:OVID) (DB:1OT) with a Overweight recommendation. This initiation matches the same-day rating action on October 9, 2026, where Cantor Fitzgerald initiated coverage with an O
- RTTNews · Aug 20, 10:38 PM EDTAfter-hours Gainers: HOWL Jumps 90%, MODD To Begin Pivot Pump Rollout, BIVI Awaits Long COVID Data(RTTNews) – The SPDR S&P Biotech ETF (XBI), a broad benchmark for the U.S. biotech sector, fell 3.64% during regular trading Thursday but edged 0.21% higher in after-hours trading. Among the notable biotech gainers in after-hours trading were Werewolf Therapeutics, which is advan
- Zacks · Aug 18, 12:00 PM EDTWhat Makes Ovid Therapeutics (OVID) a Strong Momentum Stock: Buy Now?Does Ovid Therapeutics (OVID) have what it takes to be a top stock pick for momentum investors? Let's find out.
- Zacks · Aug 13, 9:50 AM EDTOvid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue EstimatesOvid Therapeutics (OVID) delivered earnings and revenue surprises of +20.00% and +388.67%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 6, 10:00 AM EDTOutlook Therapeutics, Inc. (OTLK) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseOutlook Therapeutics, Inc. (OTLK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks · Aug 6, 9:50 AM EDTLexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Lags Revenue EstimatesLexicon (LXRX) delivered earnings and revenue surprises of 0.00% and -88.73%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 5, 10:00 AM EDTEarnings Preview: Ovid Therapeutics (OVID) Q2 Earnings Expected to DeclineOvid Therapeutics (OVID) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- RTTNews · Apr 8, 2:21 AM EDTWedbush Reaffirms Ovid Therapeutics At Outperform With Price Target Of $7(RTTNews) – Wedbush analysts on Tuesday reiterated Ovid Therapeutics (OVID) at Outperform rating with a price target of $7. Analyst Laura Chico noted that the upcoming KCC2 R&D Event, scheduled for April 14, 2026, is an important catalyst to watch.
- Fintel · Mar 26, 11:04 PM EDTOvid Therapeutics (OVID) Price Target Increased by 14.29% to 4.87The average one-year price target for Ovid Therapeutics (NasdaqCM:OVID) has been revised to $4.87 / share. This is an increase of 14.29% from the prior estimate of $4.26 dated February 21, 2026. The price target is an average of many targets provided by analys
- The Motley Fool · Mar 18, 2:37 PM EDTHere's Why Ovid Therapeutics Stock Popped Higher TodayOV329 may be safer and more potent than existing treatments.
- RTTNews · Mar 18, 12:36 PM EDTCoherent Stock Gains 6% Over Indium Phosphide Innovations Highlight At OFC 2026(RTTNews) – Shares of Coherent Corp. (COHR) are climbing about 6 percent on Wednesday morning trading after the company announced that it will highlight the breadth and scalability of its Indium Phosphide innovations at OFC 2026.
- Zacks · Mar 18, 7:50 AM EDTOvid Therapeutics (OVID) Q4 Earnings and Revenues Surpass EstimatesOvid Therapeutics (OVID) delivered earnings and revenue surprises of +158.71% and +195.47%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Ovid Therapeutics Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.